SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: Patient selection and perspectives

Vascular Health and Risk Management

Volumn 12, Issue , 2016, Pages 239-249

  Gurgle, Holly E ^a   White, Karen ^a   McAdam Marx, Carrie ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

A1c; Adverse effect; GLP 1 receptor agonist; SGLT2 inhibitor; Type 2 diabetes mellitus; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE PANCREATITIS; ADVERSE DRUG REACTION; BODY WEIGHT; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT SELECTION; REVIEW; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; WEIGHT REDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COST; DRUG EFFECTS; ECONOMICS; GLUCOSE BLOOD LEVEL; KIDNEY PROXIMAL TUBULE; METABOLISM; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; KIDNEY TUBULES, PROXIMAL; PATIENT SELECTION; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84973509210     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S83088     Document Type: Review

References (72)

1. CDC. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States. 2014.
2. American Diabetes Association. Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care. 2016; 39(Suppl 1): S4-S5.
3. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015; 21(Suppl 1): 1-87.
4. Byetta [prescribing information]. Amylin Pharmaceuticals, Inc.; 2014. Available from: http: //www. byettahcp. com. Accessed October 1, 2015.
5. Victoza [prescribing information]. Novo Nordisk; 2010. Available from: https: //http: //www. accessdata. fda. gov/drugsatfda_docs/ label/2010/022341lbl. pdf. Accessed October 1, 2015.
6. Bydureon [prescribing information]. Amylin Pharmaceuticals, Inc.; 2012. Available from: http: //www. accessdata. fda. gov/drugsatfda_docs/ label/2012/022200s000lbl. pdf. Accessed October 1, 2015.
7. Tanzeum [prescribing information]. GlaxoSmithKline LLC; 2014. Available from: http: //www. accessdata. fda. gov/drugsatfda_docs/ label/2014/125431s000lbl. pdf. Accessed October 1, 2015.
8. Trulicity [prescribing information]. Eli Lilly and Company; 2014. Available from: http: //pi. lilly. com/us/trulicity-uspi. pdf. Accessed October 1, 2015.
9. Lyxumia [prescribing information]. Sanofi-Aventis Group; 2013. Available from: http: //www. medsafe. govt. nz/Profs/Datasheet/l/lyxumiainj. pdf. Accessed October 1, 2015.
10. Saxenda [prescribing information]. Novo Nordisk; 2014. Available from: http: //www. novo-pi. com/saxenda. pdf. Accessed October 1, 2015.
11. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33(6): 1255-1261.
12. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(5): 1301-1310.
13. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013; 381(9861): 117-124.
14. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37(8): 2159-2167.
15. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683): 39-47.
16. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951): 1349-1357.
17. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet. 2014; 2(4): 289-297.
18. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, openlabel, active-controlled study (GetGoal-X). Diabetes Care. 2013; 36(10): 2945-2951.
19. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study. Lancet. 2008; 372(9645): 1240-1250.
20. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012; 29(10): 1260-1267.
21. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1): 84-90.
22. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. Regul Pept. 2013; 185: 1-8.
23. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009; 32(10): 1880-1886.
24. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7): 687-699.
25. Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014; 31(2): 176-184.
26. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide onceweekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013; 4(1): 53-61.
27. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23): 2247-2257.
28. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16(1): 38-47.
29. Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014; 13: 49.
30. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006; 73(2-3): 142-150.
31. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287(6): E1209-E1215.
32. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8(4): 436-447.
33. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373(9662): 473-481.
34. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014; 64(4): 731-737.
35. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a doubleblind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010; 9: 6.
36. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014; 28(3): 399-405.
37. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010; 23(3): 334-339.
38. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013; 15(8): 737-749.
39. Liu R, Li L, Chen Y, Yang M, Liu H, Yang G. Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis. Ann Med. 2014; 46(8): 664-671.
40. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther. 2010; 12(1): 11-24.
41. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 2013; 50(4): 569-577.
42. Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab. 2014; 16(3): 273-275.
43. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med. 2012; 29(11): 1412-1418.
44. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012; 14(10): 904-911.
45. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009; 25(4): 1019-1027.
46. Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012; 3(4): 157-164.
47. Invokana [prescribing information]. Janssen Pharmaceuticals, Inc.; 2013. Available from: https: //http: //www. invokanahcp. com/prescribinginformation. pdf. Accessed October, 2015.
48. Farxiga [prescribing information]. Bristol-Myers Squibb Company; 2014. Available from: http: //www1. astrazeneca-us. com/pi/pi_farxiga. pdf. Accessed October 1, 2015.
49. Jardiance [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc.; 2015. Available from: http: //docs. boehringer-ingelheim. com/ Prescribing Information/PIs/Jardiance/jardiance. pdf. Accessed October 1, 2015.
50. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4): 372-382.
51. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallelgroup, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36(12): 4015-4021.
52. Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014; 32(1): 4-11.
53. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014; 37(6): 1650-1659.
54. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014; 37(7): 1815-1823.
55. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2): 159-169.
56. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-2128.
57. FDA. gov: FDA. FDA approves Farxiga to treat type 2 diabetes [press release]. 2014 [January 8]. Available from: http: //www. fda. gov/NewsEvents/ Newsroom/PressAnnouncements/ucm380829. htm. Accessed January 5, 2016.
58. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. May 15, 2015. Available from: http: //www. fda. gov/Drugs/ DrugSafety/ucm446845. htm. Accessed October 1, 2015.
59. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015; 38(9): 1680-1686.
60. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38(9): 1687-1693.
61. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with sglt2 inhibitors. Diabetes Care. 2015; 38(9): 1638-1642.
62. IMS Health: Total Patient Tracker (TPT). July 2014 through June 2015. Extracted August 2015. File: DATA 2015-Canagliflozin DSC. Accessed November 11, 2015.
63. Imai K, Tsujimoto T, Goto A, et al. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. Diabetol Metab Syndr. 2014; 6(1): 110.
64. Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index b//30 kg/m(2) in Spain. J Med Econ. 2013; 16(7): 926-938.
65. Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012; 15(Suppl 2): 6-13.
66. Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011; 14(3): 357-366.
67. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14(36): 1-248.
68. Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015; 15: 496.
69. Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med. 2015; 32(7): 890-898.
70. FDA. gov: Food and Drug Administration. The FDA Safety Information and Adverse Event Reporting Program: Safety Information-Byetta (exenatide)-Renal Failure [press release]. 2009 [November 2]. Available from: http: //www. fda. gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm188703. htm. Accessed January 5, 2016.
71. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1608-1610.
72. Wholesale Acquisition Cost, Redbook Online®. Truven Health. Available from: http: //www. redbook. com/redbook/awp/. Accessed November 12, 2015.